ARTICLE | Top Story
FDA reviewer recs complete response for Northera
January 11, 2014 2:37 AM UTC
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) fell $1.03 (29%) to $2.50 on Friday after an FDA reviewer said there is "inadequate evidence of effectiveness" for Northera droxidopa to treat sym...